Form 4 for AXSM Axsome Therapeutics, Inc.
Accepted 2026-05-05 20:34:35 ET · period of report 2026-05-04 · accession 0001193125-26-207148 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-05-05 20:34 | 2026-05-04+ | AXSM | Jacobson Mark L. | COO | M - OptEx | $12.95 | +4,750 | 233 | New | +$61.5K |
| DMT | 2026-05-05 20:34 | 2026-05-04+ | AXSM | Jacobson Mark L. | COO | S - Sale+OE | $227.95 | -4,750 | 0 | -100% | -$1.08M |
| DMT | 2026-05-05 20:34 | 2026-05-04+ | AXSM | Jacobson Mark L. | COO | M - OptEx | $0.00 | -4,750 | 115.0K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-04 | M | A | 4,517 | $12.95 | 4,517 | D | — | — | (F1) Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| 2 | Common | Common Stock | 2026-05-04 | S | D | 4,517 | $227.94 | 0 | D | — | — | (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. (F3) Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. (F4) Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.12 and $231.97. |
| 3 | Common | Common Stock | 2026-05-05 | M | A | 233 | $12.95 | 233 | D | — | — | (F1) Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| 4 | Common | Common Stock | 2026-05-05 | S | D | 233 | $228.18 | 0 | D | — | — | (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. (F3) Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. (F5) Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.01 and $230.77. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-05-04 | M | D | 4,517 | $0.00 | 115,187 | D | $12.95 · 2020-03-19 to 2029-03-19 | 4,517 Common Stock | (F1) Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-05-05 | M | D | 233 | $0.00 | 114,954 | D | $12.95 · 2020-03-19 to 2029-03-19 | 233 Common Stock | (F1) Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |